Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinomaDaitaro Yoshikawa, Tatsuhiro Shibata|British Journal of Cancer|2009Cited by 95